Synthesis and Biological Evaluation of Imidazopyridine-Isatin Hybrids as Inhibitors of Leishmania major Growth.
Аннотация
INTRODUCTION
More than 20 different species of Leishmania cause leishmaniasis, a multifaceted disease that ranges from mild cutaneous lesions to fatal visceral forms.
METHODS
Sixteen novel hybrids were designed by covalently linking an imidazo[1,2-a]pyridine core to an isatin scaffold via a hydrazide linker, and their in vitro anti-promastigote, anti-amastigote, cytotoxicity, and molecular docking profiles were evaluated, with folate-rescue assays used to assess the anti-folate mechanism.
RESULTS
Several compounds showed potent anti-leishmanial activity compared to miltefosine, with the lead compound 5b exhibiting strong anti-promastigote (IC5 0 = 0.84 ± 0.06 μM) and anti-amastigote (IC5 0 = 1.28 ± 0.18 μM) activities, significantly surpassing miltefosine. Folic and folinic acids reversed the activity of 5b, confirming an anti-folate mechanism similar to that of the Lm-PTR1 inhibitor trimethoprim. The most active compounds showed higher selectivity indices (SI = 12.74) than miltefosine (SI = 438.03), and docking against Lm-PTR1 provided a plausible explanation for their potency, while in silico predictions indicated favorable drug-likeness and pharmacokinetic properties.
CONCLUSION
These findings highlight a promising new chemotype targeting the leishmanial folate pathway and expand the chemical diversity available for anti-leishmanial drug development.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.